High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML

Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy. High-dose therapy with autologous stem cell support has become the standard salvage therapy for patients failing chemotherapy, but there have been repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, C N, Gregory, W, Hudson, G Vaughan, Devereux, S, Goldstone, A H, Hancock, B, Winfield, D, MacMillan, A K, Hoskin, P, Newland, A C, Milligan, D, Linch, D C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362916/
https://www.ncbi.nlm.nih.gov/pubmed/10507773
http://dx.doi.org/10.1038/sj.bjc.6690718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362916/
https://www.ncbi.nlm.nih.gov/pubmed/10507773
http://dx.doi.org/10.1038/sj.bjc.6690718

Ejemplares similares